The global Bio-pharma Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Monoclonal antibodies, Recombinant growth factors, Vaccine, Recombinant hormones, Others), By Application (Oncology, Autoimmune disorder, Metabolic disorder, Hormonal disorder, Others).
The Bio-pharma Market encompasses pharmaceutical products, biologics, and biotechnology innovations aimed at treating diseases, improving patient outcomes, and advancing healthcare through biological therapies. In 2024, the bio-pharma sector includes biopharmaceutical companies, biotech startups, and research institutions engaged in drug discovery, development, and commercialization of biologically derived medicines. With advancements in genomics, proteomics, and immunotherapy, the bio-pharma market contributes to personalized medicine, precision therapies, and therapeutic breakthroughs across various disease areas.
The global Bio-pharma Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Bio-pharma Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Bio-pharma Industry include- Amgen Inc, Angelini S.p.a., AspenBio, Astellas Pharma Inc, AstraZeneca Plc, Bayer AG, Biogen Inc, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd, Ipsen Pharma, Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Co. Ltd, Vertex Pharmaceuticals Inc.
In the Biopharma market, a prominent trend is the continual advancements in bioprocessing techniques. With increasing demand for biopharmaceuticals and complex biotherapeutics, there is a growing emphasis on optimizing bioproduction processes to enhance yield, purity, and scalability. Innovations in cell culture technologies, downstream processing, and purification methods are driving efficiency improvements and cost reductions in biopharmaceutical manufacturing.
The primary driver for the Biopharma market is the expanding pipeline of biologic therapeutics. Biologics, including monoclonal antibodies, recombinant proteins, and gene therapies, are increasingly being developed to target a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. The growing understanding of disease mechanisms, coupled with advances in biotechnology and genomics, is fueling the rapid expansion of the biologics market and driving demand for biopharmaceutical manufacturing capabilities.
An opportunity in the Biopharma market lies in outsourcing and contract manufacturing services. As biopharmaceutical companies face pressure to accelerate time to market, manage costs, and mitigate risks, many are turning to outsourcing partners with specialized expertise and infrastructure. Contract manufacturing organizations (CMOs) offer flexibility, scalability, and regulatory compliance, enabling biopharma companies to streamline operations, optimize resource allocation, and focus on core competencies such as research and development.
Monoclonal antibodies (mAbs) emerge as the fastest-growing segment within the bio-pharma market. These specialized proteins are engineered to target specific antigens, offering precision and efficacy in treating a wide range of diseases. The growth of mAbs is propelled by several factors, including advancements in biotechnology, increased understanding of disease mechanisms, and the expanding therapeutic applications of mAbs across various medical fields. In oncology, mAbs play a crucial role in targeted cancer therapy, effectively targeting cancer cells while sparing healthy tissues. Moreover, mAbs are increasingly utilized in autoimmune disorders, where they modulate the immune system's response to reduce inflammation and tissue damage. Additionally, the development of mAbs for metabolic and hormonal disorders holds promise for addressing conditions such as diabetes and thyroid disorders. The versatility and therapeutic potential of mAbs, coupled with ongoing research and development efforts to enhance their efficacy and safety profiles, drive their rapid growth in the bio-pharma market. With their ability to provide targeted and personalized treatment approaches, monoclonal antibodies are poised to revolutionize the treatment landscape across various disease areas, making them a focal point of growth and innovation in the biopharmaceutical industry.
By Product
Monoclonal antibodies
Recombinant growth factors
Vaccine
Recombinant hormones
Others
By Application
Oncology
Autoimmune disorder
Metabolic disorder
Hormonal disorder
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Amgen Inc
Angelini S.p.a.
AspenBio
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
Biogen Inc
Bristol Myers Squibb Co.
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd
Ipsen Pharma
Johnson and Johnson
Merck KGaA
Novartis AG
Novo Nordisk AS
Pfizer Inc
Sanofi SA
Takeda Pharmaceutical Co. Ltd
Vertex Pharmaceuticals Inc
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Bio-pharma Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Bio-pharma Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Bio-pharma Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Bio-pharma Market Size Outlook, $ Million, 2021 to 2030
3.2 Bio-pharma Market Outlook by Type, $ Million, 2021 to 2030
3.3 Bio-pharma Market Outlook by Product, $ Million, 2021 to 2030
3.4 Bio-pharma Market Outlook by Application, $ Million, 2021 to 2030
3.5 Bio-pharma Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Bio-pharma Industry
4.2 Key Market Trends in Bio-pharma Industry
4.3 Potential Opportunities in Bio-pharma Industry
4.4 Key Challenges in Bio-pharma Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Bio-pharma Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Bio-pharma Market Outlook by Segments
7.1 Bio-pharma Market Outlook by Segments, $ Million, 2021- 2030
By Product
Monoclonal antibodies
Recombinant growth factors
Vaccine
Recombinant hormones
Others
By Application
Oncology
Autoimmune disorder
Metabolic disorder
Hormonal disorder
Others
8 North America Bio-pharma Market Analysis and Outlook To 2030
8.1 Introduction to North America Bio-pharma Markets in 2024
8.2 North America Bio-pharma Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Bio-pharma Market size Outlook by Segments, 2021-2030
By Product
Monoclonal antibodies
Recombinant growth factors
Vaccine
Recombinant hormones
Others
By Application
Oncology
Autoimmune disorder
Metabolic disorder
Hormonal disorder
Others
9 Europe Bio-pharma Market Analysis and Outlook To 2030
9.1 Introduction to Europe Bio-pharma Markets in 2024
9.2 Europe Bio-pharma Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Bio-pharma Market Size Outlook by Segments, 2021-2030
By Product
Monoclonal antibodies
Recombinant growth factors
Vaccine
Recombinant hormones
Others
By Application
Oncology
Autoimmune disorder
Metabolic disorder
Hormonal disorder
Others
10 Asia Pacific Bio-pharma Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Bio-pharma Markets in 2024
10.2 Asia Pacific Bio-pharma Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Bio-pharma Market size Outlook by Segments, 2021-2030
By Product
Monoclonal antibodies
Recombinant growth factors
Vaccine
Recombinant hormones
Others
By Application
Oncology
Autoimmune disorder
Metabolic disorder
Hormonal disorder
Others
11 South America Bio-pharma Market Analysis and Outlook To 2030
11.1 Introduction to South America Bio-pharma Markets in 2024
11.2 South America Bio-pharma Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Bio-pharma Market size Outlook by Segments, 2021-2030
By Product
Monoclonal antibodies
Recombinant growth factors
Vaccine
Recombinant hormones
Others
By Application
Oncology
Autoimmune disorder
Metabolic disorder
Hormonal disorder
Others
12 Middle East and Africa Bio-pharma Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Bio-pharma Markets in 2024
12.2 Middle East and Africa Bio-pharma Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Bio-pharma Market size Outlook by Segments, 2021-2030
By Product
Monoclonal antibodies
Recombinant growth factors
Vaccine
Recombinant hormones
Others
By Application
Oncology
Autoimmune disorder
Metabolic disorder
Hormonal disorder
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Amgen Inc
Angelini S.p.a.
AspenBio
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
Biogen Inc
Bristol Myers Squibb Co.
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd
Ipsen Pharma
Johnson and Johnson
Merck KGaA
Novartis AG
Novo Nordisk AS
Pfizer Inc
Sanofi SA
Takeda Pharmaceutical Co. Ltd
Vertex Pharmaceuticals Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Monoclonal antibodies
Recombinant growth factors
Vaccine
Recombinant hormones
Others
By Application
Oncology
Autoimmune disorder
Metabolic disorder
Hormonal disorder
Others
The global Bio-pharma Market is one of the lucrative growth markets, poised to register a 13.2% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Amgen Inc, Angelini S.p.a., AspenBio, Astellas Pharma Inc, AstraZeneca Plc, Bayer AG, Biogen Inc, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd, Ipsen Pharma, Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Co. Ltd, Vertex Pharmaceuticals Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume